Biotech firm secures exclusive rights to novel injection

Anhui Anke Biotechnology Group announced it has secured an exclusive agency agreement with Shanghai Baoji Pharmaceutical's subsidiary, Suzhou Shengji Pharmaceutical, for its Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection (SJ02). The agreement, effective as of July 9, 2025, grants Anhui Anke and its subsidiary, Anke Pharmaceutical, exclusive marketing and sales rights for SJ02 in mainland China, Hong Kong, and Macau. SJ02, a long-acting recombinant follicle-stimulating hormone, awaits market approval and could become the first of its kind approved in China. Suzhou Shengji Pharmaceutical has a registered capital of CNY 64,575,476. The company anticipates the partnership will enhance its product portfolio, market position, and profitability in the assisted reproductive technology sector.